{
    "ticker": "MBIO",
    "name": "Macrocure Ltd.",
    "description": "Macrocure Ltd. is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of chronic and hard-to-heal wounds. Established in 2008, Macrocure has developed its lead product, CureXcell, which is a novel cell therapy designed to accelerate the healing process for patients suffering from chronic wounds caused by diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The company\u2019s technology utilizes the patient's own immune cells, which are processed to enhance their healing properties before being reintroduced into the wound site. Macrocure aims to address the significant unmet medical need in the wound care market, which is a growing concern due to the increasing prevalence of diabetes and an aging population. The company is committed to conducting rigorous clinical trials to validate the efficacy and safety of its therapies, with the ultimate goal of bringing innovative solutions to market that improve patient outcomes and reduce healthcare costs. With a dedicated team of researchers and a robust pipeline, Macrocure is poised to make a meaningful impact in the field of regenerative medicine and wound care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rehovot, Israel",
    "founded": "2008",
    "website": "http://www.macrocure.com",
    "ceo": "Elad Kedar",
    "social_media": {
        "twitter": "https://twitter.com/macrocure",
        "linkedin": "https://www.linkedin.com/company/macrocure/"
    },
    "investor_relations": "http://www.macrocure.com/investors",
    "key_executives": [
        {
            "name": "Elad Kedar",
            "position": "CEO"
        },
        {
            "name": "Michael K. W. Wong",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapy",
            "products": [
                "CureXcell"
            ]
        }
    ],
    "seo": {
        "meta_title": "Macrocure Ltd. | Innovative Cell Therapies for Wound Care",
        "meta_description": "Explore Macrocure Ltd., a biotechnology company dedicated to developing innovative therapies for chronic wound healing. Discover our lead product, CureXcell, and our commitment to improving patient outcomes.",
        "keywords": [
            "Macrocure",
            "CureXcell",
            "Wound Care",
            "Regenerative Medicine",
            "Chronic Wounds",
            "Cell Therapy"
        ]
    },
    "faq": [
        {
            "question": "What is Macrocure known for?",
            "answer": "Macrocure is known for its innovative cell therapy product, CureXcell, designed for the treatment of chronic wounds."
        },
        {
            "question": "Who is the CEO of Macrocure?",
            "answer": "Elad Kedar is the CEO of Macrocure Ltd."
        },
        {
            "question": "Where is Macrocure headquartered?",
            "answer": "Macrocure is headquartered in Rehovot, Israel."
        },
        {
            "question": "What are Macrocure's main products?",
            "answer": "Macrocure's main product is CureXcell, a cell therapy for wound healing."
        },
        {
            "question": "When was Macrocure founded?",
            "answer": "Macrocure was founded in 2008."
        }
    ],
    "competitors": [
        "APLS",
        "MACK",
        "CRBP",
        "FOLD"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "VRTX",
        "BMY"
    ]
}